R. Whiting

发表

Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro

R. Eglen, R. U. Clague, A. Strachan, 1985, British journal of pharmacology.

Muscarinic receptor subtypes: a critique of the current classification and a proposal for a working nomenclature.

R. Eglen, R. Whiting, 1986, Journal of autonomic pharmacology.

Characteristics of 5‐HT3 binding sites in NG108‐15, NCB‐20 neuroblastoma cells and rat cerebral cortex using [3H]‐quipazine and [3H]‐GR65630 binding

R M Eglen, E. Wong, N. Sharif, 1991, British journal of pharmacology.

The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro

E. Wong, H. Parnes, R. Eglen, 1995, British journal of pharmacology.

(R) and (S) RS 56532: Mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity

E. Wong, R. Eglen, D. Bonhaus, 1994, Neuropharmacology.

Pharmacological characterization of 5HT3 receptors in rat cerebral cortex, NG108-15 and NCB-20 neuroblastoma cells using [3H]quipazine binding

N. Sharif, D. Loury, A. Michel, 1990 .

Heterogeneity of vascular muscarinic receptors.

R. Eglen, R. Whiting, 1990, Journal of autonomic pharmacology.

Negative and positive inotropic responses to muscarinic agonists in guinea pig and rat atria in vitro.

R. Eglen, R. Whiting, W. Montgomery, 1988, The Journal of pharmacology and experimental therapeutics.

The interaction of parafluorohexahydrosiladiphenidol at muscarinic receptors in vitro

R. Eglen, A. Michel, R. Whiting, 1990, British journal of pharmacology.

Comparison of the muscarinic receptors of the guinea-pig oesophageal muscularis mucosae and trachea in vitro.

R. Eglen, R. Whiting, 1988, Journal of autonomic pharmacology.

Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.

R. Eglen, W. Stanley, K. Lee, 1998, Journal of cardiovascular pharmacology.

Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase

R. Eglen, B. Li, D. Bonhaus, 1997, British journal of pharmacology.

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAKâ•’906), a Novel Selective D₂/D₃ Receptor Antagonist: A Phase 1 Randomized, Placeboâ•’Controlled Singleâ•’ and Multipleâ•’Dose Escalation Study in Healthy Participants

B. Darpo, D. Combs, R. Whiting, 2021 .

Affinity of muscarinic receptor antagonists for three putative muscarinic receptor binding sites

A. Michel, R. Whiting, R. Delmendo, 1989, British journal of pharmacology.

Methoctramine, a polymethylene tetraamine, differentiates three subtypes of muscarinic receptor in direct binding studies.

A. Michel, R. Whiting, Anton D. Michel, 1988, European journal of pharmacology.

Binding characteristics of the muscarinic receptor subtype of the NG108-15 cell line

A. Michel, R. Whiting, E. Stefanich, 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

The human astrocytoma cell line 1321 N1 contains M2‐glandular type muscarinic receptors linked to phosphoinositide turnover

A. Michel, R. Whiting, E. Kunysz, 1989, British journal of pharmacology.

Stimulation of inositol phosphate production in clonal HSDM1C1 cells by endothelins and sarafotoxin.

N. Sharif, R. Whiting, 1990, Biochemical pharmacology.

The neuropeptide bradykinin stimulates phosphoinositide turnover in HSDM1C1 cells: B2-antagonist-sensitive responses and receptor binding studies

N. Sharif, R. Whiting, 1993, Neurochemical Research.

Identification of B2-bradykinin receptors in guinea pig brain regions, spinal cord and peripheral tissues

N. Sharif, R. Whiting, 1991, Neurochemistry International.

Characterization of muscarinic receptors mediating release of epithelial derived relaxant factor (EpDRF) in guinea-pig isolated trachea

R. Eglen, M. Taylor, G. Harris, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations

K. Bley, R. L. Jones, H. Wise, 2006, British journal of pharmacology.

Assessment of imiloxan as a selective α2B‐adrenoceptor antagonist

D. Loury, A. Michel, R. Whiting, 1990 .

Animal pharmacology of nicardipine and its clinical relevance.

R. Whiting, 1987, The American journal of cardiology.

The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets

R. Eglen, R. Whiting, 1988, British journal of pharmacology.

M3 muscarinic receptors on murine HSDM1C1 cells: Further functional, regulatory, and receptor binding studies

N. Sharif, K. Wong, R. Eglen, 2004, Neurochemical Research.

Analogs of thyrotropin-releasing hormone (TRH): Receptor affinities in brains, spinal cords, and pituitaries of different species

N. Sharif, Z. To, R. Whiting, 1991, Neurochemical Research.

Radioligand binding characteristics of the chicken cardiac muscarinic receptor

A. Michel, R. Whiting, 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

The pharmacological properties of the peptide, endothelin

R. Eglen, A. Michel, R. Whiting, 1989, British journal of pharmacology.

Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin.

R. Alvarez, R. Eglen, L. Chang, 1991, Prostaglandins.

Interaction of p-F-HHSiD (p-Fluoro-hexahydrosila-difenidol) at muscarinic receptors in guinea-pig trachea

R. Eglen, R. Whiting, C. Cornett, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

Competitive and non‐competitive antagonism exhibited by ‘selective’ antagonists at atrial and ileal muscarinic receptor subtypes

R. Eglen, R. Whiting, R.M. Eglen, 1987, British journal of pharmacology.

Muscarinic activity of McN‐A‐343 and its value in muscarinic receptor classification

R. Eglen, A. Michel, R. Whiting, 1987, British journal of pharmacology.

The binding of [3H]4-diphenylacetoxy-N-methylpiperidine methiodide to longitudinal ileal smooth muscle muscarinic receptors.

A. Michel, R. Whiting, 1990, European journal of pharmacology.

Thepharmacological properties ofthepeptide, endothelin

N. Sharif, R. Eglen, A. Michel, 1989 .

Dopamine D2-receptors mediate hypothermia in mice: ICV and IP effects of agonists and antagonists

N. Sharif, A. Michel, R. Whiting, 1991, Neurochemical Research.

Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.

S. Unger, A. Kluge, A. Michel, 1982, Journal of medicinal chemistry.

First pharmacological characterization of TRH receptors linked to phosphoinositide hydrolysis in GH3 pituitary cells using agonist specificity of eight TRH analogs.

N. Sharif, Z. To, R. Whiting, 1989, Biochemical and biophysical research communications.

Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo

R. Eglen, W. Smith, R. Clark, 1995, British journal of pharmacology.

RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.

R. Eglen, W. Smith, C. Lee, 1993, The Journal of pharmacology and experimental therapeutics.

Characterization of 5‐HT3 and ‘atypical’ 5‐HT receptors mediating guinea‐pig ileal contractions in vitro

R. Eglen, R. Whiting, L. Walsh, 1990, British journal of pharmacology.

A pharmacological comparison of [3H]GBR12935 binding to rodent striatal and kidney homogenates: Binding to dopamine transporters?

N. Sharif, R. Eglen, R. Whiting, 1992, Neurochemistry International.

Direct labeling of rat M3-muscarinic receptors by [3H]4DAMP.

A. Michel, R. Whiting, E. Stefanich, 1989, European journal of pharmacology.

The interaction of methoctramine and himbacine at atrial, smooth muscle and endothelial muscarinic receptors in vitro

R. Eglen, R. Whiting, I. Dainty, 1988, British journal of pharmacology.

Methoctramine reveals heterogeneity of M2 muscarinic receptors in longitudinal ileal smooth muscle membranes.

A. Michel, R. Whiting, 1988, European journal of pharmacology.

N,N-6-bis-[2-(3,4-dihydroxybenzyl)pyrrolidinyl]hexane, a potent, selective, orally active dopamine analog with hypotensive and diuretic activity☆

R. Eglen, J. Muchowski, A. Michel, 1995 .

The mechanism of the antihypertensive action of -methyldopa in hypertensive rats.

A. Roach, R. Whiting, M. D. Day, 1973, European journal of pharmacology.

Antihypertensive 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones.

A. Michel, R. Clark, D. B. Repke, 1983, Journal of medicinal chemistry.

PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site

A. Michel, R. Whiting, E. Stefanich, 1989, British journal of pharmacology.

On the interaction of gallamine with muscarinic receptor subtypes.

A. Michel, R. Whiting, R. Delmendo, 1990, European journal of pharmacology.

1 Pharmacology and Structure-Activity Relationships of α2-Adrenoceptor Antagonists

A. Michel, R. Clark, R. Whiting, 1986 .

BRL 8242 (2-[2-benzimidazolyl]-amino-2-imidazoline dihydrochloride), a new inhibitor of dopamine-beta-hydroxylase with antihypertensive activity.

M. Palfreyman, R. Whiting, R. Poyser, 1976, European journal of pharmacology.

Characterization of the interaction of the cervane alkaloid, imperialine, at muscarinic receptors in vitro

R. Eglen, G. Harris, R. Whiting, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis

J. Jasper, G. Luehr, R. Whiting, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Identification of a single x1-adrenoceptor corresponding to the alA-subtype in rat submaxillary gland

D. Loury, R. Whiting, Antón, 2006 .

Identification of a single α1‐adrenoceptor corresponding to the α1A‐subtype in rat submaxillary gland

D. Loury, A. Michel, R. Whiting, 1989 .

Functional and direct binding studies using subtype selective muscarinic receptor antagonists

A. Michel, R. Whiting, E.L. Kunysz, 1988, British journal of pharmacology.

Characterization of the muscarinic receptor subtype mediating contractions of the guinea‐pig uterus

R. Eglen, A. Michel, R. Whiting, 1989, British journal of pharmacology.

Analysis of muscarinic cholinoceptors mediating phosphoinositide hydrolysis in guinea pig cardiac muscle.

A. Ford, R. Eglen, R. Whiting, 1992, European journal of pharmacology.

Multidisciplinary analysis of muscarinic receptors in guinea-pig isolated ileum, atria and uterus in vitro

A. Ford, R. Eglen, G. Harris, 1992 .

Differential effects of pertussis toxin on muscarinic responses in isolated atria and smooth muscle.

R. Eglen, M. M. Huff, R. Whiting, 1988, Journal of autonomic pharmacology.

Acute desensitization of muscarinic receptors in the isolated guinea-pig ileal longitudinal muscle.

R. Eglen, N. Adham, R. Whiting, 1992, Journal of autonomic pharmacology.

Direct binding studies on ileal and cardiac muscarinic receptors

A. Michel, R. Whiting, 1987, British journal of pharmacology.

Problems associated with the application of the Cheng-Prusoff relationship to estimate atropine affinity constants using functional tissue responses.

R. Eglen, R. Whiting, 1989, Life sciences.

Differential effects of pertussis toxin and lithium on muscarinic responses in the atria and ileum: evidence for receptor heterogeneity

R. Eglen, M. M. Huff, R. Whiting, 1987, British journal of pharmacology.

Estimation of apparent agonist affinity constants using desensitization of the ileal muscarinic receptor.

R. Eglen, R. Whiting, 1987, The Journal of pharmacology and experimental therapeutics.

Cellular action of nicardipine.

A. Michel, R. Whiting, 1989, The American journal of cardiology.

Determination of the muscarinic receptor subtype mediating vasodilatation.

R. Eglen, R. Whiting, 1985, British journal of pharmacology.

The interaction of hexamethonium with muscarinic receptor subtypes in vitro

R. Eglen, A. Michel, R. Whiting, 1989, British journal of pharmacology.

Quantitative autoradiography demonstrates selective modulation of rat brain regional dopamine (D1 and D2) receptor subtypes after chronic manipulation of dietary salt

N. Sharif, R. Eglen, R. Whiting, 1995, Neurochemical Research.

Syntheses and hypotensive properties of substituted 2-aminotetralins.

J. Muchowski, A. Kluge, R. Clark, 1985, Journal of pharmaceutical sciences.

BRL 13776: A NOVEL ANTIHYPERTENSIVE AGENT WITH INTERESTING MONOAMINE DEPLETING PROPERTIES

M. Palfreyman, R. Whiting, J. Melrose, 1977, British journal of pharmacology.

The 5‐HT3 receptor antagonist, RS‐56812, enhances delayed matching performance in monkeys

W. J. Jackson, E. Wong, J. Buccafusco, 1996, Neuroreport.

Antihypertensive 1-acyl-4-[2-(1,4-benzodioxan-2-yl)-2-hydroxyethylamino]pip eridines.

C. Brown, A. Kluge, L. Hedley, 1987, Journal of pharmaceutical sciences.

Differential affinities of TRH analogs at the mammalian spinal cord TRH receptor: Implications for therapy in spinal injuries

N. Sharif, Z. To, A. Michel, 1989, Neuroscience Letters.

Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro

R. Eglen, R. Whiting, 1989, British journal of pharmacology.

RS‐61756‐007: a potent and selective thromboxane receptor (TP) agonist

R. Eglen, R. Whiting, 1989, The Journal of pharmacy and pharmacology.

Differences between the α2‐adrenoceptor in rat submaxillary gland and the α2A‐ and α2B‐adrenoceptor subtypes

D. Loury, A. Michel, R. Whiting, 1989 .

5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum

R. Eglen, D. Clarke, D. Craig, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

Desensitization and functional antagonism by β‐adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity

R. Eglen, R. Whiting, W. Montgomery, 1991, British journal of pharmacology.

Agonist action of indole derivatives at 5- HT1 -like, 5-HT2, 5-HT3 and 5-HT4 receptors in vitro

R. Eglen, R. Whiting, L. Walsh, 1992 .

Chronic manipulation of dietary salt modulates renal physiology and kidney dopamine receptor subtypes: functional and autoradiographic studies.

N. Sharif, R. Eglen, K. Lake, 1995, General pharmacology.

Differences between the cx2-adrenoceptor in rat submaxillary gland and the a2A- and a2B-adrenoceptor subtypes

A. Michel, R. Whiting, Dana N. Lodry, 2006 .

Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice

A. Michel, R. Whiting, T. Kilfoil, 1989, Neuropharmacology.

Dog cerebral cortex contains μ-, δ- and κ-opioid receptors at different densities: apparent lack of evidence for subtypes of the κ-receptor using selective radioligands

N. Sharif, A. Michel, R. Whiting, 1990, Brain Research.

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D2/D3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

B. Darpo, D. Combs, R. Whiting, 2021, Clinical pharmacology in drug development.

Pharmacological characterization of the N-methyl-d-aspartate (NMDA) receptor-channel in rodent and dog brain and rat spinal cord using [3H]MK-801 binding

N. Sharif, R. Whiting, J. L. Nunes, 1991, Neurochemical Research.

The action of (±)L-660,863 [(±)3-(3-amino-1,2,4-oxadiazole-5-yl)-quinuclidine] at muscarinic receptor subtypes in vitro

A. Ford, E. Wong, R. Eglen, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety.

E. Wong, B. Costall, R. Naylor, 1993, European journal of pharmacology.

Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol.

R. Eglen, D. Clarke, R. Bond, 1990, The Journal of pharmacology and experimental therapeutics.

Antihypertensive aminotetralins related to labetalol and medroxalol.

C. Brown, R. Clark, D. B. Repke, 1986, Journal of pharmaceutical sciences.

Identification of B(2)-bradykinin receptors in guinea pig brain regions, spinal cord and peripheral tissues.

N. Sharif, R. Whiting, 1991, Neurochemistry international.

Muscarinic receptors subtypes: problems of classification

R. Eglen, R. Whiting, 1985 .

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis

M. Osinski, R. Whiting, S. Williams, 2022, Journal of experimental pharmacology.

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2/D3 Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants

H. Okamoto, R. Whiting, K. Kudou, 2021, Clinical pharmacology in drug development.

Pharmacological differences between atrial and smooth muscle muscarinic receptors

R. Eglen, M. M. Huff, R. Whiting, 1986 .

An improved technique for the continuous measurement of arterial blood pressure in the conscious unrestrained cat.

R. Whiting, M. D. Day, 1972, British Journal of Pharmacology.

Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [3H]GBR12935 binding and [3H]dopamine uptake

N. Sharif, A. Michel, R. Whiting, 1989, Neurochemistry International.

Comparison of the positive chronotropic response to 5-hydroxytryptamine with beta-adrenoceptor agonists on the guinea pig atria in vitro.

R. Eglen, R. Whiting, 1989, Journal of cardiovascular pharmacology.

First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.

G. Giaccone, D. Hong, M. Cristea, 2021 .